Patient kits – from CO2 removal to adequate oxygenation
Our preconfigured patient kits consist of an oxygenator, tubings, the DP3 pump head and integrated pressure sensors (IPS). They enable treatments of acute and chronic heart and lung failure. From neonates up to adults.
All blood-contact surfaces of our patient kits are coated with the x.ellence® coating. This multi-layer coating is made of heparin and albumin.
Novalung ultimate kit
Novalung ultimate kit is the first MDR-certified and FDA-cleared tubing kit for long-term ECLS treatment.*
The Novalung ultimate kit is designed for prolonged respiratory/cardiopulmonary continuous flow life support, providing assisted extracorporeal circulation and physiological gas exchange of the blood.
*MDR: 29 days, FDA: >6 hours
Novalung kits
The Novalung kit is a pump-driven medical device which enables the extracorporeal blood gas exchange of carbon dioxide and oxygen by diffusion across a gas-permeable and plasma-tight polymethylpentene (PMP) membrane, as well as temperature control of blood by a heat exchanger compartment.
The Novalung kit has integrated pressure sensors (IPS) which are used to monitor the blood pressure inside the extracorporeal circuit.
Novalung kits are available in different sizes and configurations. They are certified* for an application period for up to 29 days and enable treatment of acute and chronic heart and lung failure:
- XLung kit 230
- MiniLung kit ¼“
- MiniLung petite kit
*CE 0123
iLA activve kits
iLA activve XLung kit
The iLA activve XLung kit is a pump-driven system which enables the extracorporeal blood gas exchange of carbon dioxide and oxygen by diffusion across a gas-permeable and plasma-tight polymethylpentene (PMP) membrane, as well as temperature control of blood.
The video explains the principle of physical gas exchange using a Novalung XLung kit as an example.
Discover more e-learning modules on Heart & Lung Campus.
[1] Voigt, I. et al. (2021). Efficacy and safety of ECG-synchronized pulsatile extracorporeal membrane oxygenation in the clinical setting: The SynCor Trial. Artif Organs, 46(3), 387-397